<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920219-0166</DOCNO><DOCID>920219-0166.</DOCID><HL>   OTC Focus:   Index Drops 1.6% as Biotech Shares   And Health Care Issues Pace Decline   ----   By Anne Newman and Dave Pettit   Staff Reporters of The Wall Street Journal</HL><DATE>02/19/92</DATE><SO>WALL STREET JOURNAL (J), PAGE C6</SO><IN>STOCK INDEXES (NDX)OTC GENERAL MARKET COMMENT (OTC)STOCK MARKET, OFFERINGS (STK)U.S. STOCK MARKET STATISTICS (STT)</IN><NS>STOCK AND OTHER INDEXES (NDX)STOCK andamp; OTHER MARKET NEWS (STK)</NS><RE>NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   NEW YORK -- Biotechnology and health care stocks and lastyear's over-the-counter leaders bore the brunt of a 1.6% fallin smaller issues as the rising yield on long-term bonds gavestocks some competition.   The Nasdaq Composite Index fell 10.02 to 626.41. Thedecline was led by a 2.4% fall in the Nasdaq 100 Index of thelargest nonfinancial issues as leaders such as CostcoWholesale fell 2 to 58 1/4, Microsoft declined 1 to 118 1/4and Sun Microsystems fell 1 3/8 to 31. Declining stocksoutpaced advancers, 1,343 to 925; 152 shares climbed to newhighs, however, while 34 fell to new lows. Total OTC volumerose to 218.7 million shares from 206.3 million Friday.</LP><TEXT>   The OTC &quot;pullback is overdue in view of what has happenedto interest rates,&quot; said Gail Dudack, market analyst at S.G.Warburg andamp; Co. Sagging bond prices have continued to nudgelong-term rates higher over the past month. In early January,the 30-year Treasury was yielding just 7.39%. &quot;With ratesedging back up to {nearly} 8%, bonds are becoming morecompetitive with equities,&quot; she said.   Biotechnology shares swooned as bellwether Amgen fell 3 to62 1/4; Chiron slipped 1 to 50 3/4; Genzyme tumbled 2 to 433/4, and Pioneer Hi-Bred International, which makesgenetically engineered agricultural products, toppled 4 to64. Among all stocks, the Dow Jones index of biotechnologystocks was the worst-performing group for the day with a 5.2%decline; the group also has been the most sluggish this yearwith a 19% fall.   Biotechnology stocks will fall further as investors remainskittish about companies without earnings or with prospectsof big profits still far in the future, suggests L. KeithMullins of Smith Barney, Harris Upham andamp; Co. Selling in thegroup &quot;will scare the devil out of them&quot; in the short term,Mr. Mullins says, adding that he expects the group to leadOTC shares another 10% to 15% lower. Longer term, however,Mr. Mullins said that he expects the biotechnology industrywill remain a leader of the OTC market. Despite this year'sslump, the group is 42% higher than a year earlier.   Investors punished young companies that are stillreporting losses as they develop their drugs. Immune Responsetumbled 3 3/8 to 26 1/8 after the San Diego company said thatfourth-quarter losses narrowed to one cent a share from 15cents a share; losses for the year, however, widened to 23cents a share from 12 cents a year earlier. Synergen slipped2 3/4 to 47 1/4. The Boulder, Colo., company reported thatfourth-quarter losses narrowed to nine cents a share from 24cents a share a year earlier and losses for the year narrowedto 36 cents a share from 42 cents.   Centocor tumbled 4 3/4 to 41 1/4 after a 2 3/8-point fallFriday, when a Robertston Stephens andamp; Co. analyst warned thatthe company might not have a big advantage over rival Xoma inits race to win final regulatory approval for a drug to treatseptic shock. Xoma eased 3/4 to 23 1/2.   The selling even spread to health maintenance providers,second among the day's worst-performing groups. U.S.Healthcare plunged 4 1/4 to 49, although the company raisedits quarterly dividend to 14 cents a share from 11 cents.PacifiCare Health Systems fell 2 3/4 to 55 3/4; Ramsay-HMOslipped 1 1/2 to 25. Among makers of medical products, St.Jude Medical slipped 1 3/4 to 45 3/4; Stryker fell 2 1/2 to41, and Tokos Medical, which makes prenatal monitoringdevices, tumbled 3 to 35.   Handex Environmental plunged 8 1/4, or 27%, to 22 3/4.Late Friday, it said Shell Oil will reduce the amount ofbusiness it does with the Morganville, N.J., concern. Revenuefrom Shell, a unit of the Royal Dutch/Shell Group, maydecline by as much as 25% in 1992 from 1991, it said.   Analysts yesterday trimmed their estimates of Handexearnings for this year, Dow Jones Professional InvestorReport said. Alex. Brown andamp; Sons' Hugh F. Holman, for example,reduced his forecast to $1.10 a share from $1.25.   HealthCare Compare dropped 2 3/4 to 37 1/4 despite thecompany's report that its fourth-quarter net income rose to17 cents a share from eight cents a share a year ago. Revenuerose to $19.6 million from $12.1 million.   Immune Response lost 3 3/8 to 26 1/8 after it reported afourth-quarter loss of one cent a share, compared with ayear-earlier deficit of 15 cents a share. Analysts hadexpected a loss of about three cents a share in the latestperiod, according to First Call, a unit of Thomson FinancialNetworks.   Synergen slipped 2 3/4 to 47 1/4. It posted afourth-quarter loss of nine cents a share, compared with adeficit of 24 cents a share last year. The mean First Callestimate was a loss of 11 cents in the latest quarter.   Michael Foods jumped 2 5/8 to 18 after the companydisclosed plans to begin marketing a reduced cholesterolliquid-egg product. The company said its offering, to becalled &quot;Simply Eggs,&quot; will be different from similar existingproducts because it will contain both egg whites and yolks.Simply Eggs will be marketed as a joint venture with SKWNature's Products Inc.   Intelligent Electronics added 3/4 to 28 1/4, while FutureNow jumped 3 1/4 to 18 1/2. The companies plan a strategicalliance, under which Intelligent Electronics will obtain a32% interest in Future Now. In exchange for the holding,Intelligent will transfer substantially all of its resellercenter to Future Now.   Buffets Inc. gained 2 5/8 to 36 1/2 after the companyreported fourth-quarter net income of 18 cents a share, upfrom 10 cents a share last year. Sales increased to $47.7million from $36 million.   Protective Life gained 1 to 23 3/4 after it reportedfourth-quarter earnings of 81 cents a share, up from 66 centsa share a year earlier.   Smithfield Foods lost 1 1/2 to 19 1/4. The companyreported net income 66 cents a share for its third quarter,ended Feb. 2, down from 90 cents a share.   CBandamp;T Financial gained 3 1/4 to 16 1/4. The West Virginiabank was profiled in this week's edition of Barron'smagazine. The company has remained strong despite a weaklocal economy, Barron's said.   Crown Andersen lost 5 to 18. The stock fell 2 on Fridayafter the company reported earnings of 19 cents a share forits first quarter, ended Dec. 31, down from 21 cents a sharea year earlier.</TEXT></DOC>